The 2nd U.S. Cir­cuit Court of Ap­peals granted a pre­lim­i­nary in­junc­tion forc­ing Ac­tavis to keep sell­ing Na­menda IR, an Alzheimer’s drug taken twice a day.

Modern Healthcare - - LATE NEWS -

Ac­tavis had planned to pull the drug and re­place it with Na­menda XR, which is taken once a day. The state of New York al­leged the move was meant to sti­fle com­pe­ti­tion from gener­ics in vi­o­la­tion of an­titrust laws. By the time generic ver­sions of the old drug were ex­pected to be­come avail­able in July, doc­tors and pa­tients wouldn’t want to switch to them be­cause of the con­ve­nience of tak­ing the drug once, not twice a day, New York al­leged.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.